Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of tanezumab versus placebo and oxycodone in knee or hip osteoarthritis
2009-013329-41Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in knee osteoarthritis (OA) and hip osteoarthritis (4 arms), sponsored by Pfizer. Primary endpoints: Change from baseline to week 16 in WOMAC pain subscale for tanezumab versus placebo and Change from baseline to week 16 in WOMAC pain subscale for tanezumab versus oxycodone. Started Oct 2009; status: completed.
02
Drugs
tanezumab
03
Conditions
knee osteoarthritis (OA)hip osteoarthritis
Beyond the preview
Go deeper on 2009-013329-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013329-41.